Tesamorelin constituent — phase 3 figure
- Reported quantity
- 2 mg
- Frequency
- Once daily
- Study duration
- 26–52 weeks
This figure comes from CT-endpoint visceral adipose trials in a defined clinical population.
Protocols · Growth Hormone
Tesamorelin + Ipamorelin: literature-reported ranges
This blend pairs the GHRH analogue with the largest randomised dataset in its class with the most selective secretagogue in its class. As with every blend on this site, the combination itself has no published controlled study; only the two constituents do.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Compound at a glance
- Class
- Stabilised GHRH analogue + selective secretagogue blend
- Reported half-life
- Approximately 30 minutes and 2 hours respectively
- Routes used in the literature
- Subcutaneous
- Also written as
- —
What the published studies reported
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
Ipamorelin constituent — human phase 2 figure
- Reported quantity
- 0.03 mg/kg per administration
- Frequency
- Twice daily in the trial arms
- Study duration
- Up to 7 days
The ipamorelin human record is short-duration post-operative work, not long-term.
Dosage chart
These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.
Tesamorelin · 10 mg Vial
Tesamorelin is dosed at 1 mg–2 mg daily by subcutaneous injection in educational protocols, typically at night. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 3.0 mL bacteriostatic water per 10 mg vial → ~3.33 mg/mL concentration.
- Standard daily dose
- 2 mg (2000 mcg) once daily subcutaneously (FDA-approved protocol).
- Easy measuring
- At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
- Storage
- Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F); reconstituted: refrigerate and use within 7 days with bacteriostatic water.
Standard FDA-Approved Protocol (3.0 mL = ~3.33 mg/mL)
| Week | Daily Dose (mg / mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 1 mg / 1000 mcg | 30 units (0.30 mL) |
| Weeks 2–12+ | 2 mg / 2000 mcg | 60 units (0.60 mL) |
Ipamorelin · 10 mg Vial
Ipamorelin is dosed at 100 mcg–250 mcg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 3.0 mL bacteriostatic water → ~ 3.33 mg/mL concentration.
- Typical daily range
- 100–300 mcg once daily (gradual titration recommended).
- Easy measuring
- At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33 mcg on a U-100 insulin syringe.
- Storage
- Lyophilized: 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within ~4 weeks.
Standard / Gradual Approach (3.0 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg | 3 units (0.03 mL) |
| Weeks 3–4 | 150 mcg | 5 units (0.05 mL) |
| Weeks 5–8 | 200 mcg | 6 units (0.06 mL) |
| Weeks 9–12 | 250 mcg | 8 units (0.08 mL) |
Reconstitution maths
Blends are commonly presented as a combined 10 mg or 12 mg vial. In 2 mL that is 5–6 mg/mL of total peptide; the useful figure is per-peptide, from the certificate.
Open the reconstitution calculatorHow to read these figures
- Trial durations of the two constituents differ by an order of magnitude — the blend inherits neither dataset.
- Stability differs between the two peptides in solution, which is a real argument against premixed vials.
- Glucose-metabolism monitoring featured in the tesamorelin trials and is part of reading that dataset honestly.
Sources and citations
No peer-reviewed primary literature reporting administered quantities exists for this item. Anything circulating online about quantities is anecdote rather than evidence, and this page will not reproduce it. The database links below are kept so you can check for yourself as new work is published.
Search the databases yourself
Read the Tesamorelin + Ipamorelin research briefOther growth hormone compounds
AOD-9604hGH fragment 176-191CJC-1295 (no DAC)Tetra-substituted GHRH (1-29) analogueCJC-1295 (no DAC) + IpamorelinGHRH analogue + selective ghrelin-receptor agonist blendCJC-1295 with DACGHRH analogue with albumin-binding drug affinity complex
All research protocolsPeptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.